6531-08-4

Usage

InChI:InChI=1/C5HCl3N2O/c6-3-1-2(5(8)11)4(7)10-9-3/h1H

Upstream product

• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 

Downstream Products

• 115983-46-5 7-Chlor-3-(dimethylamino)pyridazino<4,3-f>-1,2,4-oxadiazepin-5(2H)-on 
• 199850-43-6 3,6-dichloro-N-(2-chloro-3-pyridinyl)pyridazine-4-carboxamide 
• 204649-13-8 3,6-dichloro-N-methyl-N-phenylpyridazine-4-carboxamide 
• 185419-99-2 3,6-dichloro-N-(4-trifluoromethyl-2-hydroxyphenyl)pyridazine-4-carboxamide 
• 35857-93-3 3,6-dichloropyridazine-4-carbonitrile 
• 1336909-93-3 6-(4-fluorophenylamino)-3-isopropoxypyridazine-4-carboxylic acid ((R)-1-isopropylpiperidin-3-ylmethyl)amide 

Relevant academic research and scientific papers

ACTIVE COMPOUND COMBINATIONS

The present invention relates to active compound combinations, in particular within a fungicide composition, which comprise as compound (A) a compound of formula (I) and as compound (B) a further fungicidally active compound as specified below. Moreover, the invention relates to compositions comprising such compound combination and to the use of the compound combinations and the fungicide compositions as biologically active agent, especially for control of phytopathogenic fungi in crop protection and in the protection of industrial materials and as plant growth regulators.

6,7-DIAZAINDAZOLE AND 6,7-DIAZAINDOLE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

IMIDAZOLE DERIVATIVES

The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before.

(HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS

The present invention relates to compounds of formula (I), wherein A and B, X, Y, Z, and R1-R6 are as defined in the claims, for the treatment of neurological disorders.

TRIAZOLO COMPOUNDS

The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.

ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF

The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on al nAChRs in a mammal by administering an effective amount of a compound of Formula I.

PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.

QUINOLONE ANALOGS AND METHODS RELATED THERETO

The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.

PYRIDAZINE DERIVATIVES FOR INHIBITING BETA AMYLOID PEPTIDE PRODUCTION

The present invention relates to novel compounds that inhibit the production of β- amyloid peptide (1-42), processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

A convenient approach to heterocyclic building blocks: Synthesis of novel ring systems containing a [5,6]pyrano[2,3-c]pyrazol-4(1H)-one moiety

Starting from commercially available educts, a straightforward synthetic route to new heterocyclic building blocks is exemplified with the one- or two-step synthesis of tri-, tetra-, or pentacyclic ring systems. Representatives of the following novel ring systems are prepared from 3-methyl-1-phenyl-2- pyrazolin-5-one and the corresponding o-haloarenecarbonyl chloride using calcium hydroxide in refluxing 1,4-dioxane: pyrimidino[4′,5′:5,6]pyrano[2, 3-c]pyrazol-4(1H)-one, thieno[3′,2′:5,6]pyrano[2,3c]pyrazol-4-(1H)- one, thieno[3′,4′:5,6]pyrano[2,3-c]pyrazol-4(1H)-one, thieno[3″,2″:4′,5′]thieno-[2′,3′:5,6] pyrano[2,3-c]pyrazol-4(1H)-one, [1,3]dioxolo[5′,6′][1] benzothieno[2′,3′:5,6]pyrano-[2,3-c]pyrazol-4(1H)-one, pyridazino[4′,3′:5,6]pyrano[2,3-c]pyrazol-4(1H)-one, and pyrazolo[4″,3″:5′,6′]pyrido[3′,4′:5,6] pyrano[2,3-c]pyrazol-6(9H)-one. While the latter two ring systems are directly obtained due to a spontaneous intramolecular substitution reaction, in the other reactions uncyclised 4-aroylpyrazol-5-ols are produced, which are cyclised into the target heterocycles in a subsequent synthetic step (i.e. treatment with NaH in DMF). Detailed NMR spectroscopic investigations (1H-, 13C-, 15N-) with the obtained compounds were undertaken to unambiguously prove the new structures.